Immunome Inc.
IMNM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001472012
In the last 90 days, Immunome Inc. insiders filed 0 open-market purchases and 7 sales; 202 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Immunome Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 26 | 24 | −2 |
| Shares | 2.41M | 2.39M | −13.8K (−0.6%) |
| Value | $7.78M | $10.7M | +$2.95M (+37.9%) |
New holders (2)
Institutions that held Immunome Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Advisor Group Holdings, Inc. | 1,229 | $5.00K | 0.00% |
| BNP Paribas Arbitrage, SA | 67 | $297 | 0.00% |
Sold out (4)
Institutions that held Immunome Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Citadel Advisors LLC | 13,159 | $42.0K |
| Susquehanna International Group, LLP | 12,052 | $39.0K |
| Titleist Asset Management, Ltd. | 10,000 | $32.0K |
| Tower Research Capital LLC (TRC) | 2,489 | $8.00K |